Section Arrow
Quote
MIRM.NASDAQ
- Mirum Pharmaceuticals
Quotes are at least 15-min delayed:2026/02/28 03:31 EST
Regular Hours
Last
 92.29
+0.12 (+0.13%)
Day High 
95.46 
Prev. Close
92.17 
1-M High
109.28 
Volume 
1.02M 
Bid
91.05
Ask
92.56
Day Low
90.8 
Open
91.01 
1-M Low
90.26 
Market Cap 
5.52B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 103.79 
20-SMA 102.86 
50-SMA 91.43 
52-W High 109.28 
52-W Low 36.8801 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.84/0.04
Enterprise Value
5.84B
Balance Sheet
Book Value Per Share
4.88
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
336.89M
Operating Revenue Per Share
2.42
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ENSCEnsysce Biosciences0.6232+0.22885+58.03%-- 
EDSAEdesa Biotech2.2+0.65+41.94%-- 
IBRXImmunityBio9.78+0.23+2.41%-- 
GOSSGossamer Bio0.4249+0.0229+5.70%-- 
QNCXQuince Therapeutics0.1257-0.0121-8.78%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.